Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

[1]  P. Vermersch,et al.  Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis , 2011, The Lancet Neurology.

[2]  L. Kappos,et al.  Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients , 2011, Multiple sclerosis.

[3]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[4]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[5]  X. Montalban,et al.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results , 2010, Multiple sclerosis.

[6]  C. Pozzilli,et al.  Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment , 2009, Journal of the Neurological Sciences.

[7]  L. Meyerson,et al.  Statistical methods for the analysis of relapse data in MS clinical trials , 2009, Journal of the Neurological Sciences.

[8]  L. Kappos,et al.  The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL , 2009, Journal of Neurology.

[9]  Yinshan Zhao,et al.  Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  S. Sorbi,et al.  Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis , 2007, European Neurology.

[11]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[12]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[13]  H. Zwibel.  Glatiramer acetate in treatment‐naïve and prior interferon‐β‐1b‐treated multiple sclerosis patients * , 2006, Acta neurologica Scandinavica.

[14]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[15]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[16]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.